Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lifitegrast - Novartis

Drug Profile

Lifitegrast - Novartis

Alternative Names: Lifitegrast; SAR-1118; SAR-1119; SHP606; SPD606; Xiidra

Latest Information Update: 04 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Sunesis Pharmaceuticals
  • Developer Novartis; SARcode Bioscience; Shire
  • Class Anti-inflammatories; Antiallergics; Antipsoriatics; Benzofurans; Eye disorder therapies; Isoquinolines; Propionic acids; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Lymphocyte function-associated antigen-1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes
  • No development reported Allergic conjunctivitis; Atopic dermatitis; Diabetic macular oedema; Ocular inflammation; Psoriasis

Most Recent Events

  • 01 Jul 2019 Novartis acquires lifitegrast from Takeda
  • 09 May 2019 Novartis to acquire lifitegrast from Takeda
  • 21 Jan 2019 Registered for Dry eyes in Australia (Ophthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top